FI3392252T3 - Pyrimidopyridazinoniyhdisteet ja niiden käyttö - Google Patents
Pyrimidopyridazinoniyhdisteet ja niiden käyttö Download PDFInfo
- Publication number
- FI3392252T3 FI3392252T3 FIEP18175788.1T FI18175788T FI3392252T3 FI 3392252 T3 FI3392252 T3 FI 3392252T3 FI 18175788 T FI18175788 T FI 18175788T FI 3392252 T3 FI3392252 T3 FI 3392252T3
- Authority
- FI
- Finland
- Prior art keywords
- alkyl
- compound
- use according
- optionally substituted
- phenyl
- Prior art date
Links
- VSGHANRHWUFOHC-UHFFFAOYSA-N 2h-pyrimido[5,4-c]pyridazin-3-one Chemical class N1=CN=CC2=NNC(=O)C=C21 VSGHANRHWUFOHC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000003053 piperidines Chemical class 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- FQXFKRRYNPIDCF-UHFFFAOYSA-N 2-morpholin-4-yl-4-[4-(piperazin-1-ylmethyl)anilino]-6h-pyrimido[4,5-d]pyridazin-5-one;hydrochloride Chemical compound Cl.C=12C(=O)NN=CC2=NC(N2CCOCC2)=NC=1NC(C=C1)=CC=C1CN1CCNCC1 FQXFKRRYNPIDCF-UHFFFAOYSA-N 0.000 claims 1
- BJTVZYGZPOJXBU-UHFFFAOYSA-N 2-phenyl-4-(4-piperazin-1-ylanilino)-2,3,4,4a,6,7,8,8a-octahydro-1H-pyrimido[4,5-d]pyridazin-5-one Chemical compound C12C(=O)NNCC2NC(C=2C=CC=CC=2)NC1NC(C=C1)=CC=C1N1CCNCC1 BJTVZYGZPOJXBU-UHFFFAOYSA-N 0.000 claims 1
- DEJRBJRLVAFXHD-UHFFFAOYSA-N 2-phenyl-4-[4-(piperazin-1-ylmethyl)anilino]-2,3,4,4a,6,7,8,8a-octahydro-1H-pyrimido[4,5-d]pyridazin-5-one Chemical compound C12C(=O)NNCC2NC(C=2C=CC=CC=2)NC1NC(C=C1)=CC=C1CN1CCNCC1 DEJRBJRLVAFXHD-UHFFFAOYSA-N 0.000 claims 1
- BEBYZOYXFUTCAH-UHFFFAOYSA-N 4-[4-(4-ethylpiperazin-1-yl)anilino]-2-phenyl-2,3,4,4a,6,7,8,8a-octahydro-1H-pyrimido[4,5-d]pyridazin-5-one Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1C2C(=O)NNCC2NC(C=2C=CC=CC=2)N1 BEBYZOYXFUTCAH-UHFFFAOYSA-N 0.000 claims 1
- VWXRNRYGLAGGLW-UHFFFAOYSA-N 4-[4-(morpholine-4-carbonyl)anilino]-2-phenyl-2,3,4,4a,6,7,8,8a-octahydro-1H-pyrimido[4,5-d]pyridazin-5-one Chemical compound C=1C=C(NC2C3C(=O)NNCC3NC(N2)C=2C=CC=CC=2)C=CC=1C(=O)N1CCOCC1 VWXRNRYGLAGGLW-UHFFFAOYSA-N 0.000 claims 1
- MGJNCBCDNVORJM-UHFFFAOYSA-N 4-[4-[(4-ethylpiperazin-1-yl)methyl]anilino]-2-phenyl-2,3,4,4a,6,7,8,8a-octahydro-1H-pyrimido[4,5-d]pyridazin-5-one Chemical compound C1CN(CC)CCN1CC(C=C1)=CC=C1NC1C2C(=O)NNCC2NC(C=2C=CC=CC=2)N1 MGJNCBCDNVORJM-UHFFFAOYSA-N 0.000 claims 1
- DRPFCKWXHLVXLR-UHFFFAOYSA-N 4-[4-[bis(2-hydroxyethyl)amino]anilino]-2-phenyl-2,3,4,4a,6,7,8,8a-octahydro-1H-pyrimido[4,5-d]pyridazin-5-one Chemical compound C1=CC(N(CCO)CCO)=CC=C1NC1C2C(=O)NNCC2NC(C=2C=CC=CC=2)N1 DRPFCKWXHLVXLR-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 claims 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical class C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526525P | 2011-08-23 | 2011-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3392252T3 true FI3392252T3 (fi) | 2024-01-08 |
Family
ID=46829884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18175788.1T FI3392252T3 (fi) | 2011-08-23 | 2012-08-23 | Pyrimidopyridazinoniyhdisteet ja niiden käyttö |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8729079B2 (enExample) |
| EP (4) | EP4327886A3 (enExample) |
| JP (1) | JP5993010B2 (enExample) |
| CN (2) | CN103974955B (enExample) |
| BR (1) | BR112014003981A2 (enExample) |
| CA (1) | CA2846187A1 (enExample) |
| DK (2) | DK3392252T3 (enExample) |
| ES (2) | ES2690971T3 (enExample) |
| FI (1) | FI3392252T3 (enExample) |
| HU (1) | HUE065564T2 (enExample) |
| IL (1) | IL231082A (enExample) |
| MX (1) | MX361458B (enExample) |
| PL (1) | PL2748166T3 (enExample) |
| WO (1) | WO2013028818A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4327886A3 (en) * | 2011-08-23 | 2024-05-22 | Libertas Bio, Inc. | Pyrimido- pyridazinone compounds and use thereof |
| AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
| WO2018187294A1 (en) * | 2017-04-03 | 2018-10-11 | Asana Biosciences, Llc | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof |
| CN118105392A (zh) * | 2017-04-28 | 2024-05-31 | 自由生物有限公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
| CN111961035B (zh) * | 2019-05-20 | 2022-11-01 | 南京科技职业学院 | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 |
| CN114174298B (zh) * | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
| CN113583026B (zh) * | 2020-04-30 | 2024-06-14 | 杭州英创医药科技有限公司 | 一类含有稠合三环结构的化合物 |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| AU2022421224A1 (en) * | 2021-12-22 | 2024-06-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| JP2025506783A (ja) * | 2022-02-23 | 2025-03-13 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | グサシチニブの固体形態 |
| WO2023192989A2 (en) * | 2022-04-01 | 2023-10-05 | Azkarra Therapeutics, Inc. | Phthalazinone compounds as parp7 inhibitors |
| WO2025020171A1 (en) * | 2023-07-27 | 2025-01-30 | Libertas Bio, Inc. | Crystalline forms of a jak/syk inhibitor |
| AU2024299978A1 (en) | 2023-07-27 | 2026-03-12 | Libertas Bio, Inc. | Solid state forms of gusacitinib |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756508A (fr) * | 1969-09-24 | 1971-03-01 | Takeda Chemical Industries Ltd | Derives de pyrimidopyridazine |
| CA1004223A (en) * | 1972-05-12 | 1977-01-25 | Theodor Denzel | Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters |
| JPS4948695U (enExample) | 1972-07-29 | 1974-04-27 | ||
| JPS50101387A (enExample) * | 1974-01-16 | 1975-08-11 | ||
| CA1052046A (en) | 1974-01-21 | 1979-04-03 | American Cyanamid Company | Unsymmetrically substituted 1,4-dioxane-2,5-diones |
| US5369086A (en) | 1993-04-28 | 1994-11-29 | Zeneca Limited | N-benzotriazoles |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| JPH0948695A (ja) | 1995-08-02 | 1997-02-18 | Toshiba Ceramics Co Ltd | シリコン単結晶の製造方法 |
| JP2002504550A (ja) | 1998-02-25 | 2002-02-12 | ファルマシア・アンド・アップジョン・カンパニー | 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体 |
| JP3635238B2 (ja) | 1998-11-10 | 2005-04-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖの複製を阻害するピリミジン類 |
| PL207755B1 (pl) * | 2000-09-22 | 2011-01-31 | N V Organon | Bicykliczny związek heteroaromatyczny, zawierająca go kompozycja farmaceutyczna i jego zastosowania |
| WO2002088095A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| AU2003212634A1 (en) | 2002-03-11 | 2003-09-22 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| CA2577467C (en) | 2004-09-30 | 2013-05-28 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-heterocyclyl pyrimidines |
| WO2006066361A1 (en) | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| CN101189234B (zh) | 2005-03-25 | 2011-08-17 | 泰博特克药品有限公司 | Hcv的杂二环抑制剂 |
| EP1869037B1 (en) | 2005-03-25 | 2011-07-27 | Tibotec Pharmaceuticals | Heterobicylic inhibitors of hvc |
| US20080194656A1 (en) | 2005-04-29 | 2008-08-14 | Monique Jenny Marie Berwaer | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists |
| US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| US20070161670A1 (en) | 2006-01-09 | 2007-07-12 | Bristol-Myers Squibb Company | Process for the preparation of substituted heterocycles |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
| PT2698062E (pt) * | 2006-12-28 | 2015-10-19 | Abbvie Inc | Inibidores da poli (adp-ribose) polimerase |
| KR20090130051A (ko) | 2007-03-14 | 2009-12-17 | 엑셀리시스, 인코포레이티드 | 헤지호그 경로의 억제제 |
| TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| JP2012506386A (ja) | 2008-10-21 | 2012-03-15 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１２０受容体アゴニストおよびその使用 |
| MX2012004846A (es) * | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| WO2011079105A1 (en) * | 2009-12-23 | 2011-06-30 | Abbott Laboratories | Novel thienopyrrole compounds |
| US8440662B2 (en) | 2010-10-31 | 2013-05-14 | Endo Pharmaceuticals, Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
| EP4327886A3 (en) * | 2011-08-23 | 2024-05-22 | Libertas Bio, Inc. | Pyrimido- pyridazinone compounds and use thereof |
| US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
| AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
| CN118105392A (zh) * | 2017-04-28 | 2024-05-31 | 自由生物有限公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
-
2012
- 2012-08-23 EP EP23201319.3A patent/EP4327886A3/en active Pending
- 2012-08-23 DK DK18175788.1T patent/DK3392252T3/da active
- 2012-08-23 HU HUE18175788A patent/HUE065564T2/hu unknown
- 2012-08-23 ES ES12756865T patent/ES2690971T3/es active Active
- 2012-08-23 CN CN201280051788.8A patent/CN103974955B/zh active Active
- 2012-08-23 EP EP18175788.1A patent/EP3392252B1/en active Active
- 2012-08-23 MX MX2014002112A patent/MX361458B/es active IP Right Grant
- 2012-08-23 EP EP12756865.7A patent/EP2748166B1/en active Active
- 2012-08-23 ES ES18175788T patent/ES2969977T3/es active Active
- 2012-08-23 CN CN201810492306.1A patent/CN108707151B/zh active Active
- 2012-08-23 PL PL12756865T patent/PL2748166T3/pl unknown
- 2012-08-23 WO PCT/US2012/051980 patent/WO2013028818A1/en not_active Ceased
- 2012-08-23 JP JP2014527282A patent/JP5993010B2/ja active Active
- 2012-08-23 BR BR112014003981A patent/BR112014003981A2/pt not_active IP Right Cessation
- 2012-08-23 EP EP18182723.9A patent/EP3404029A3/en not_active Withdrawn
- 2012-08-23 DK DK12756865.7T patent/DK2748166T3/en active
- 2012-08-23 FI FIEP18175788.1T patent/FI3392252T3/fi active
- 2012-08-23 US US13/592,511 patent/US8729079B2/en active Active
- 2012-08-23 CA CA2846187A patent/CA2846187A1/en active Pending
-
2014
- 2014-02-23 IL IL231082A patent/IL231082A/en active IP Right Grant
- 2014-04-03 US US14/244,183 patent/US9382277B2/en active Active
-
2016
- 2016-04-25 US US15/137,950 patent/US10183944B2/en active Active
-
2018
- 2018-11-30 US US16/206,395 patent/US10647720B2/en active Active
-
2020
- 2020-02-25 US US16/800,111 patent/US20200190095A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2647116C (en) | Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as gaba receptor ligands | |
| HRP20201107T1 (hr) | Heteroaril amidi kao inhibitori proteinske agregacije | |
| JP2013509438A5 (enExample) | ||
| PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
| ES2650225T3 (es) | Compuestos (Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo con doble actividad como agonistas inversos de H1/antagonistas de 5-HT2A | |
| TW200640907A (en) | Heterocyclic substituted piperazines with CXCR3 antagonist activity | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| NZ629442A (en) | Heterocyclyl compounds as mek inhibitors | |
| CA2829123A1 (en) | Quinazolinediones and their use | |
| RU2012102094A (ru) | Новые азабициклогексаны | |
| AU2015304883A1 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
| MX2009006871A (es) | Compuestos heterociclicos con actividad antagonista de cxcr3. | |
| PH12018501041A1 (en) | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | |
| HRP20170217T1 (hr) | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| NZ600365A (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
| HRP20160641T1 (hr) | Fuzionirani triciklički spojevi kao inhibitori raf kinaze | |
| JP2016040262A5 (enExample) | ||
| JP2009533393A5 (enExample) | ||
| ES2622754T3 (es) | Acoplamiento catalizado por Pd de pirazol amidas | |
| RU2014138032A (ru) | Новые соединения-антагонисты рецептора нейрокинина 1 | |
| CA2903107A1 (en) | Coumarin derivatives and methods of use in treating hyperproliferative diseases | |
| JP2014524475A5 (enExample) | ||
| RU2008105304A (ru) | Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы | |
| US20100168099A1 (en) | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |